Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background and objective Alcoholic liver disease (ALD) encompasses a spectrum of liver conditions caused by excessive alcohol consumption, including fatty liver, alcoholic hepatitis, and cirrhosis. Both phenotypical and biochemical changes in gonadal hormones are observed across these stages. This study aimed to evaluate the clinical, biochemical, and hormonal abnormalities in patients with varying degrees of ALD and to assess their correlation with disease severity. Methodology A cross-sectional study was conducted at Lady Hardinge Medical College, New Delhi, involving 150 patients with ALD who were categorized into three groups: fatty liver (n=45, 30.0%), alcoholic hepatitis (n=30, 20.0%), and chronic liver disease (CLD) (n=75, 50.0%). Clinical, biochemical, and hormonal profiles were assessed, including hemoglobin (Hb), platelet count (PLT), serum albumin, total protein, serum testosterone, and various stigmata of chronic alcoholism. Results The spectrum of ALD revealed that fatty liver was present in 30.0% (n=45) of patients, alcoholic hepatitis in 20.0% (n=30), and cirrhosis in 50.0% (n=75). In the fatty liver group, 60.0% (n=27) had Grade 1 severity, 28.9% (n=13) had Grade 2, and 11.1% (n=5) had Grade 3. Biochemical parameters showed a marked decrease in Hb in cirrhosis (9.24 ± 2.93 g/dl) compared to fatty liver (11.97 ± 3.10 g/dl) and alcoholic hepatitis (11.10 ± 3.01 g/dl). PLT was lowest in cirrhosis (170,718.67 ± 124,250.94 cells/mm³), and serum albumin levels were significantly lower in cirrhosis (2.69 ± 0.67 g/dl). Total bilirubin levels were highest in alcoholic hepatitis (4.76 ± 2.80 mg/dl), while liver enzymes serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) were markedly elevated in alcoholic hepatitis (336.90 ± 156.10 and 232.60 ± 125.93 IU/L, respectively). Hormonal analysis indicated hyperestrogenemia in 57.8% (n=26) of fatty liver patients and 70% (n=21) of those with alcoholic hepatitis and cirrhosis (n=53). Hyperprolactinemia was observed in 62.7% (n=28) of fatty liver patients, 55.6% (n=17) of those with alcoholic hepatitis, and 53.3% (n=40) with cirrhosis. Decreased serum testosterone was most prominent in cirrhosis (57.3%, n=43). Conclusions Patients with ALD exhibit significant clinical and biochemical abnormalities across all stages. Gonadal hormone levels, particularly estrogen and testosterone, are notably altered and may not always correlate with disease severity. Elevated serum testosterone and sex hormone-binding globulin (SHBG) levels, alongside the presence of chronic alcoholism stigmata, are indicative of disease progression. The association of hyperestrogenemia with gynaecomastia and hypoandrogenemia with sparse pubic/axillary hair underscores the need for further research on hormonal markers in ALD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624427PMC
http://dx.doi.org/10.7759/cureus.73178DOI Listing

Publication Analysis

Top Keywords

alcoholic hepatitis
32
fatty liver
28
liver
12
liver disease
12
disease severity
12
clinical biochemical
12
serum testosterone
12
alcoholic
10
patients alcoholic
8
alcoholic liver
8

Similar Publications

Background: (Benth.) Baker is a perennial shrub endemic to the Tibetan Plateau. Its seeds are traditional Tibetan medicine for treating jaundice, hepatitis, purulent tonsillitis, diphtheria, and parasitosis.

View Article and Find Full Text PDF

Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.

View Article and Find Full Text PDF

Chronic liver disease (CLD) is a leading cause of global morbidity and mortality, necessitating effective preventive strategies. Growing evidence is linking coffee consumption with reduced risk of disease progression in various CLDs, including metabolic dysfunction associated steatotic liver disease (MASLD), alcoholic liver disease, hepatitis B and C, autoimmune hepatitis, and a reduction in the risk of hepatocellular carcinoma development. Coffee, a globally consumed beverage, contains bioactive compounds like caffeine, chlorogenic acids, diterpenes, and polyphenols, which may offer hepatoprotective benefits through anti-inflammatory, antioxidant, and metabolic regulatory effects.

View Article and Find Full Text PDF

Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.

Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.

View Article and Find Full Text PDF

Aim Of The Study: Chronic hepatitis C (CHC) infection remains one of the most prevalent chronic liver disease worldwide. A sustained virological response (SVR) can be achieved at high rates for CHC patients receiving direct-acting antivirals (DAAs). However, even small subsets of patients achieving SVR still have a risk of developing hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF